HOME >> MEDICINE >> NEWS
OHSU scientists test medication to treat involuntary weight loss

s to develop and test a medication that would have the same effect. This medication, and others in its class, have excellent oral absorption, which also enhances their appeal as drug candidates.

In this research, the scientists gave both normal mice and mice with a cachexia-like syndrome Neurocrine's orally-administered medication that blocks the MC4 receptor in the brain. In both cases, the animals' appetites increased and their metabolic rates decreased, ultimately resulting in the resumption of normal growth and accumulation of muscle mass. Researchers now hope to conduct clinical trials where both healthy human patients and those suffering from cachexia receive related oral medications to determine the drug's safety and effectiveness.

"We believe the results obtained in this collaborative study with OHSU will provide an important proof-of-principle for Neurocrine's small molecule MC4 receptor antagonist program in animal models relevant for cachexia," said Alan C Foster, Ph.D., Neurocrine Fellow and head of Neurocrine's neuroscience group. Neurocrine is a San Diego-based company that is developing medications related to weight regulation. "We hope to advance an optimized molecule into the first stages of human clinical testing later this year."

"While a lot of attention is paid to the country's obesity epidemic, researchers at OHSU also investigate the other side of weight regulation which is not as well-publicized -- extreme weight loss," said Roger Cone, Ph.D., director of the Center for the Study of Weight Regulation and Associated Disorders. "Cachexia and disorders like it can have extremely serious consequences on patients. This research not only provides hope for these patients, it is also provides another important piece of the puzzle in regards to the brain's control over weight regulation."

The Center for the Study of Weight Regulation and Associated Disorders is a new research institute at Oregon Health & Science
'"/>

Contact: Jim Newman
newmanj@ohsu.edu
503 494-8231
Oregon Health & Science University
29-Mar-2005


Page: 1 2 3

Related medicine news :

1. Earlier use of prostate cancer vaccines urged by Hopkins scientists
2. Tobacco industry pays scientists to challenge secondhand smokes link to infant death risk
3. Schepens scientists regenerate optic nerve for the first time
4. OHSU scientists develop MRI approach to improve breast cancer detection
5. UCLA neuroscientists pinpoint new function for mirror neurons
6. Jefferson scientists uncover potential trigger of diabetic kidney disease
7. Johns Hopkins scientists receive presidential medals
8. UCLA brain scientists crack mystery of how alcohol causes intoxication
9. Wisconsin scientists grow critical nerve cells
10. Jefferson scientists help explain statins effects in Alzheimers disease
11. Jefferson scientists find zinc may help prevent esophageal, oral cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/24/2017)... ... July 24, 2017 , ... ... management solution focused on delivering end-to-end sleep health care at scale, indicates ... literature shows that adherence rates for positive airway pressure (PAP) therapy, the most ...
(Date:7/24/2017)... BEACH, Calif. (PRWEB) , ... July 24, 2017 , ... ... ranging from food addiction to sexual abuse, and how she has overcome them. “Forbidden ... traumatic instances in her life and how she has risen above. , In “Memories,” ...
(Date:7/24/2017)... PA (PRWEB) , ... July 24, 2017 , ... ... 2030, today CURE announced that they have enrolled over 100,000 children in their ... afflicted children born every year in areas where treatment is limited or non-existent. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical ... MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , ... Increased FDA scrutiny and growing demands to track and report adverse events place ...
(Date:7/24/2017)... ... July 24, 2017 , ... On July ... was set up, and the awarding ceremony was held successfully in Beijing. The ... of the army's health system, and national Chinese medicine experts also attended the ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/10/2017)... 2017 Locus Biosciences Inc. today announced the ... development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round ... Internet services provider, and joined by the North Carolina ... product programs targeting antibiotic resistant infections and other microbiome-related ... Dr. Rodolphe Barrangou and Dr. Charles ...
(Date:7/5/2017)... , July 5, 2017 Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... it has received approval from the Israel Securities Authority to ... (TASE). Oramed common stock will commence trading on the TASE ... the current market capitalization of the Company, it is expected ...
Breaking Medicine Technology:
Cached News: